Thrombostenin

Thrombostin is a protein that is involved in blood coagulation processes. It stimulates the synthesis of blood clotting factors such as fibrinogen and thrombin. This helps form blood clots after vascular damage.

Thrombin is the main coagulation factor and is responsible for the formation of a clot from blood plasma, which prevents

Thrombostenin is a drug for the treatment of thrombosis and thromboembolic diseases. It belongs to the group of direct-acting anticoagulants. When using thrombostanine, blood clotting increases, and as a result, large blood clots begin to dissolve, and the dissolved elements leave the bloodstream through lysed pathways.

Thrombasten is the drug of choice for acute coronary syndrome, especially in cardiogenic shock, acute stented myocardial infarction (first 2 weeks), and in emergency conditions. In patients with cardiogenic shock, early reperfusion is the main goal of therapy. In addition, thrombasten can be used in patients at high risk of developing retrothmbolytic syndrome after staging myocardial infarction.

One of the most significant problems in the treatment of venous thrombosis is resistance to treatment with standard antithrombotic drugs. In many cases, the risk of recurrent thrombus formation is quite high and its prevention remains a serious problem in clinical practice. The use of special antithrombotic drugs - that is, direct or indirect action - is of considerable interest. Some of the most important are thrombin and thrombin complex inhibitors. However, over the past 25 years, only a few drugs have been registered that can be classified in this group. Among them are heparin, dalteparin sodium, low molecular weight forms, fraxiparin and tidroparone. Low availability and high cost have shown that their use is limited, since they can only be used in a clinical setting under strict supervision. Other potential injectable agents include apixaban and rivaroxaban. These drugs have significant efficacy with a low risk of bleeding and are available for widespread use in medical practice. They provide wide penetration into the veins, influence the main clotting factors and are effective for patients with low renal function. Cryoprecipitate